Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1016/j.cell.2016.11.005 http://scihub22266oqcxt.onion/10.1016/j.cell.2016.11.005 C5512418!5512418 !27912060     free     free     free Deprecated: Implicit conversion from float 219.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 219.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Warning: imagejpeg(C:\Inetpub\vhosts\kidney.de\httpdocs\phplern\27912060 .jpg): Failed to open stream: No such file or directory in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 117       Cell 2016 ; 167 (6 ): 1525-1539.e17 Nephropedia Template TP {{tp|p=27912060 |t=2016. The Hippo Pathway Kinases LATS1/2 Suppress Cancer Immunity |pdf=|usr=}}{{27912060 }} gab.com Text The Hippo Pathway Kinases LATS1/2 Suppress Cancer Immunity JO: Cell http://www.kidney.de/pget.php?&tw=1&pmid=27912060 #FOAvip Poorly immunogenic tumor cells evade host immunity and grow even in the presence of an intact immune system, but the complex mechanisms regulating tumor immunogenicity have not been elucidated. Here, we discovered an unexpected role of the Hippo pathway in suppressing anti-tumor immunity. We demonstrate that, in three different murine syngeneic tumor models (B16, SCC7, and 4T1), loss of the Hippo pathway kinases LATS1/2 (large tumor suppressor 1 and 2) in tumor cells inhibits tumor growth. Tumor regression by LATS1/2 deletion requires adaptive immune responses, and LATS1/2 deficiency enhances tumor vaccine efficacy. Mechanistically, LATS1/2-null tumor cells secrete nucleic-acid-rich extracellular vesicles, which induce a type I interferon response via the Toll-like receptors-MYD88/TRIF pathway. LATS1/2 deletion in tumors thus improves tumor immunogenicity, leading to tumor destruction by enhancing anti-tumor immune responses. Our observations uncover a key role of the Hippo pathway in modulating tumor immunogenicity and demonstrate a proof of concept for targeting LATS1/2 in cancer immunotherapy. Twit Text FOAVip The Hippo Pathway Kinases LATS1/2 Suppress Cancer Immunity ????Cell http://www.kidney.de/pget.php?&tw=1&pmid=27912060 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=27912060 #FOAvip English Wikipedia <ref>{{Cite pmid|27912060 }}</ref> The Hippo Pathway Kinases LATS1/2 Suppress Cancer Immunity #MMPMID27912060 Moroishi T ; Hayashi T ; Pan WW ; Fujita Y ; Holt MV ; Qin J ; Carson DA ; Guan KL Cell 2016[Dec]; 167 (6 ): 1525-1539.e17 PMID27912060 show ga Poorly immunogenic tumor cells evade host immunity and grow even in the presence of an intact immune system, but the complex mechanisms regulating tumor immunogenicity have not been elucidated. Here, we discovered an unexpected role of the Hippo pathway in suppressing anti-tumor immunity. We demonstrate that, in three different murine syngeneic tumor models (B16, SCC7, and 4T1), loss of the Hippo pathway kinases LATS1/2 (large tumor suppressor 1 and 2) in tumor cells inhibits tumor growth. Tumor regression by LATS1/2 deletion requires adaptive immune responses, and LATS1/2 deficiency enhances tumor vaccine efficacy. Mechanistically, LATS1/2-null tumor cells secrete nucleic-acid-rich extracellular vesicles, which induce a type I interferon response via the Toll-like receptors-MYD88/TRIF pathway. LATS1/2 deletion in tumors thus improves tumor immunogenicity, leading to tumor destruction by enhancing anti-tumor immune responses. Our observations uncover a key role of the Hippo pathway in modulating tumor immunogenicity and demonstrate a proof of concept for targeting LATS1/2 in cancer immunotherapy. |*Immune Tolerance [MESH] |Animals [MESH] |Cancer Vaccines/immunology [MESH] |Gene Deletion [MESH] |Immunotherapy [MESH] |Mice [MESH] |Mice, Inbred BALB C [MESH] |Mice, Inbred C3H [MESH] |Mice, Inbred C57BL [MESH] |Neoplasms/*immunology [MESH] |Protein Serine-Threonine Kinases/genetics/*metabolism [MESH] |Signal Transduction [MESH] |Toll-Like Receptors/metabolism [MESH]The Hippo Pathway Kinases LATS1/2 Suppress Cancer Immunity (epmc).pdf DeepDyve Pubget Overpricing